Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in acute myeloid leukemia and MDS
- Trial result
Acute myeloid leukemia and MDS
FLAG-GO (CD33 ADC) lifts 5-year OS to 80% in frontline CBF-AML, blunting baseline mutation prognostic impact
Fludarabine/cytarabine/G-CSF (FLAG) is an intensive cytarabine-based induction/consolidation platform, and gemtuzumab ozogamicin (GO) is a CD33-directed antibody–drug conjugate; both were evaluated in a frontline…
NCT00801489 - New trial
Acute myeloid leukemia and MDS
Phase 2 haploidentical HSCT using cyclophosphamide/busulfan or fludarabine/TBI conditioning (DNA-damaging alkylators)
This National Cancer Institute (NIH Clinical Center) Phase 2, prospective, open-label transplant protocol tests whether individualized (“tailored”) dosing of conditioning chemotherapy and key supportive-care drugs…
NCT07524530 Exploratory - Trial result Spotlight
Acute myeloid leukemia and MDS
CD371/SAVVY/IL-18 Armored CAR T Clears 3/5 r/r AML in First-in-Human Pilot
CD371/SAVVY/IL-18 is a CLEC12A (CD371/CLL-1)–targeted, IL-18–secreting CAR T built with a mutated CD28 costimulatory domain to limit exhaustion; in the Phase I dose-finding study NCT06017258, 5 patients with…
NCT06017258 - New trial Spotlight
Acute myeloid leukemia and MDS
Phase I Trial of Lintuzumab-Ac-225, a CD33-targeted alpha emitter in AML
This Phase I study assesses the safety, tolerability, and optimal dosing of combination treatment with lintuzumab-Ac-225 (a CD33-targeted alpha emitter), venetoclax (a BCL-2 inhibitor), and ASTX-727 (a pairing of…
NCT06802523 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 2 Olutasidenib IDH1 inhibitor AML maintenance trial
The study aims to assess whether the single-agent investigational olutasidenib, an IDH1 inhibitor, can safely maintain remission in adult patients with IDH1-mutant AML following intensive induction and consolidation…
NCT07130695 Exploratory - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 3 Trial: Bleximenib Menin-MLL Inhibitor for Acute Myeloid Leukemia
This Phase 3 randomized, double-blind study evaluates whether adding investigational bleximenib (a Menin-MLL inhibitor) to venetoclax (BCL2 inhibitor) plus azacitidine (DNA methylation inhibitor) improves outcomes…
NCT06852222 Registrational - New trial
Acute myeloid leukemia and MDS
Phase 2/3 Trial of L-Annamycin Topoisomerase II Inhibitor in AML Remission Induction
This pivotal adaptive study evaluates L-Annamycin (a liposomal topoisomerase II inhibitor) plus Cytarabine versus placebo with Cytarabine for remission induction in adults with refractory/relapsed AML. The…
NCT06788756 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1b/2 Cladribine Trial: DNA Synthesis Inhibitor in AML
This open-label study at MD Anderson Cancer Center evaluates oral cladribine (a DNA synthesis inhibitor) in combination with low dose cytarabine (a DNA synthesis inhibitor) and venetoclax (a BCL-2 inhibitor) to…
NCT07053020 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase Ia/Ib Revumenib Menin-MLL Inhibitor Trial in Pediatric Acute Leukemia
This study at M.D. Anderson evaluates the safety and efficacy of revumenib (Menin-MLL inhibitor) with daunorubicin (Topoisomerase II inhibitor), cytarabine (DNA synthesis inhibitor), and gemtuzumab ozogamicin in…
NCT07052994 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase I/II bortezomib 26S proteasome inhibitor with CPX-351 in TP53-mutated AML
This trial by the Masonic Cancer Center, University of Minnesota evaluates safety and preliminary efficacy of bortezomib (a 26S proteasome inhibitor) combined with CPX-351 (a liposomal formulation of daunorubicin and…
NCT07008638 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 2 Quizartinib FLT3 Inhibitor Trial in AML Maintenance
This Phase 2, multi-center, randomized, open-label trial by Daiichi Sankyo evaluates two dose levels of quizartinib, a small molecule FLT3 inhibitor, as maintenance therapy post induction and consolidation in adult…
NCT06824168 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1b Venetoclax BCL-2 inhibitor trial comparing HMA versus intensive induction in AML
This therapeutic trial at The Methodist Hospital Research Institute evaluates a novel blood-based 5hmC biomarker in adults with de novo AML by comparing HMA regimens (azacitidine or decitabine plus venetoclax with…
NCT07060001 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 2 Momelotinib Trial: JAK1/JAK2 inhibitor for low-risk MDS anemia
This trial evaluates different momelotinib doses to optimize treatment safety, pharmacokinetics, and efficacy in reducing red blood cell transfusion needs for patients with low-risk myelodysplastic syndrome (LR-MDS)…
NCT06847867 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase I/II Study of AZD2962, an IRAK4 inhibitor, in Hematologic Neoplasms
This open-label, multicentre trial evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AZD2962—an IRAK4 inhibitor—administered as monotherapy in a dose-escalation…
NCT07064122 First-in-human - New trial
Acute myeloid leukemia and MDS
Phase 1 zedenoleucel trial: multi-target primed allogeneic T cell therapy
This Phase 1 multicenter open-label study from Marker Therapeutics, Inc. evaluates safety and efficacy of escalating flat doses of investigational zedenoleucel, a multi-target primed allogeneic T cell therapy…
NCT06552416 First-in-human - New trial
Acute myeloid leukemia and MDS
Phase 1/2 trial of Debio 1562M, novel inhibitor of aberrant leukemic signaling.
This first-in-human, open-label study evaluates Debio 1562M administered intravenously every 3 weeks to determine safety, tolerability, and optimal dosing in patients with relapsed or refractory acute myeloid…
NCT06969430 First-in-human - New trial
Acute myeloid leukemia and MDS
Phase 1b Olutasidenib IDH1 inhibitor trial in IDH1-mutated myeloid cancers
This study from MD Anderson Cancer Center evaluates the safety and tolerability of olutasidenib-based combination regimens in relapsed/refractory AML or MDS/MPN with co-signaling mutations. Patients are assigned to…
NCT07032727 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase I: Blinatumomab, bispecific CD19-directed antibody, combined with early memory T-cell infusion protocol
This Phase I trial at St. Jude Children's Research Hospital tests the safety and feasibility of an early CD45RA-depleted donor lymphocyte infusion following a TCRαβ-depleted haploidentical transplant in patients with…
NCT07052370 First-in-human - New trial
Acute myeloid leukemia and MDS
Pilot Trial: Venetoclax (BCL2 inhibitor) in pediatric AML chemotherapy substitution
Investigators aim to assess whether substituting two cycles of intensive chemotherapy (Ida-FLA and VIA) for standard regimens in intermediate and high risk pediatric AML patients yields comparable or improved…
NCT07059975 Exploratory - Trial result
Acute myeloid leukemia and MDS
Ven-CLAG-M Nabs 65% CR in Adverse-Risk or Relapsed AML
Venetoclax, a BCL-2 inhibitor, was layered onto the intensive CLAG-M backbone (cladribine 5 mg/m² ×5 days, cytarabine 1.5 g/m² ×5, mitoxantrone 16/18 mg/m² ×3, plus G-CSF priming) in a first-in-human Phase 1…
NCT04797767 - New trial
Acute myeloid leukemia and MDS
Phase 1 Trial of miRisten, a cell growth molecule blocker, for relapsed/refractory AML
This Phase 1 trial at City of Hope Medical Center evaluates miRisten administered via IV infusion on a multi-day schedule to determine its safety, tolerability, and optimal dosing in adult patients with…
NCT07025564 First-in-human - New trial
Acute myeloid leukemia and MDS
Phase 1 trial of atezolizumab PD-L1 mAb combined with CIML natural killer cells in AML.
This study aims to determine the maximum tolerated dose of cytokine-induced memory-like NK cells with atezolizumab and IL-2 in relapsed/refractory acute myelogenous leukemia. Participants have various genetic AML…
NCT07011004 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1b dexamethasone (glucocorticoid) plus venetoclax trial in treatment-naïve AML.
This investigator-initiated single-arm study at the University of Vermont evaluates the safety and tolerability of adding dexamethasone to venetoclax-based low-intensity therapy in adult AML patients ineligible for…
NCT07014462 Exploratory - Trial result
Acute myeloid leukemia and MDS
Bexmarilimab (Clever-1 macrophage checkpoint) + azacitidine logs 80% ORR and 13.4-mo OS in relapsed high-risk MDS
Bexmarilimab, an antibody that blocks the macrophage/blast checkpoint Clever-1, was combined with standard azacitidine in the phase 1/2 BEXMAB trial (NCT05428969). In 35 hypomethylating-agent–refractory MDS patients,…
NCT05428969 - New trial
Acute myeloid leukemia and MDS
Phase 1b/2 APVO436 bispecific anti-CD123/CD3 antibody study
This open-label, dose-finding trial evaluates APVO436 with venetoclax and azacitidine in adult patients with newly diagnosed CD123+ AML ineligible for induction therapy. Conducted across multiple U.S. centers and…
NCT06634394 - Trial result
Acute myeloid leukemia and MDS
SENTI-202 Logic-Gated CD33/FLT3 CAR-NK Cells Show 44% MRD-Negative CR in First-in-Human AML Study
SENTI-202 is a ready-made cell therapy that uses natural killer (NK) cells engineered to target cancer in a smart and precise way. It includes an “OR-gate” sensor that activates the cells when they detect either of…
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.